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Abstract: 
Over recent years the research focus within the field of respiratory drug delivery has 
broadened to include a wide range of potential applications for inhalation by delivering 
drugs not just onto the lung mucosa but across it. The range of drugs being assessed is 
broad and includes both current and novel therapies and there are a growing number of 
additives that appear capable of enhancing systemic absorption. Comprehensive 
characterisation of drug delivery to the lungs is a complex task involving determination 
of delivered, deposited and for systemically targeted drugs absorbed dose and therefore 
difficult to simulate in vitro, thus in vivo whole animal models are still key in inhaled 
drug development. Because of the anatomical complexities and interspecies differences 
in the lungs appropriate choice of species and drug delivery method is vital during study 
design. New delivery devices designed specifically for animal studies and more 
sophisticated methods to determine drug deposition and absorption after inhalation are 
improving the information now derived from these studies.  
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1. Introduction 
In modern medicine drug  inhalation has primarily been used as a modality for treating 
local respiratory diseases and over 500 million people now carry the classical metred 
dose inhaler with them on a daily basis [1]. Over the last 20 years the research focus 
within the field of respiratory drug delivery has broadened to include a wider range of 
potential applications for inhalation by delivering drugs not just onto the airway but 
across it [2,3]. This change in thinking was catalysed by a number of factors including 
the emergence of biotherapeutics with their associated delivery issues and a greater 
understanding of the absorption properties of the lungs. The physiology and anatomy of 
the lungs offer a unique portal for drug delivery. Its’ large surface area, decreased 
metabolic capacity (relative to the gastrointestinal tract),  a relatively thin alveolar 
epithelium in the lower airways and rich blood supply have been found to facilitate rapid 
drug absorption and adequate bioavailabilities via the lungs [4,5]. Inhalation has the 
added benefit of being a non-invasive route of delivery, particularly appealing for all the 
biomolecules currently restricted to parenteral use [6,7,5]. 
 
1.1 The human lungs as organs of absorption 
The human lungs are composed of a series of subdividing airways with airway calibre 
diminishing from the trachea, through the bronchi and bronchioles (known as the 
airways) and finally to the alveolar ducts and sacs, the site of gas exchange [8]. There are 
significant differences between the cells located in the airway and the alveolar 
epithelium, with the airways composed of pseudostratified columnar epithelium 
containing mucus and cilia cells that constitute the mucociliary clearance mechanism of 
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the lungs. In the alveoli the columnar epithelial cells are replaced primarily by broad and 
thin Type I cells alongside their progenitor Type II cells that also produce lung surfactant. 
In this region too are found the alveolar macrophages. The thickness of epithelium 
decreases from 50-60m in the upper airway to 0.2m in the alveolar region. In terms of 
volume the conducting airways (trachea, bronchi and bronchioles) constitute 
approximately 150ml while the respiratory zone of the lungs compromises some 2.5-3 
litres in volume. The alveolar region makes up the vast proportion of the overall surface 
area of the lungs with an alveolar surface area of more than 100m2 compared to only a 
few metres square in the airways[8]. The large surface area of the lungs and the highly 
perfused nature of the organ mean that conditions are well suited for drug uptake into the 
systemic circulation. The alveolar regions of the lower lungs appear to be the optimum 
site for systemic drug absorption of many drugs including the majority of peptides and 
proteins[6], while small, hydrophobic molecules are absorbed rapidly by diffusion 
throughout the lungs[6]. The routes of drug absorption across the airway epithelium can 
include passive and active transport mechanisms involving paracellular and transcellular 
transport, pore formation, vesicular transport, and drainage into the lymphatics depending 
on the drug and site of absorption [912]. 
 
The lung does however present barriers to systemic absorption of drugs. The very 
branched architecture of the respiratory tract means that efficient delivery of a drug to the 
lower lungs, where the majority of drugs are best absorbed, is difficult. Efficient delivery 
to the lower  lungs after inhalation is essential if adequate absorption to achieve the 
desired systemic concentration is to be facilitated. Pharmaceutical inhalation technology 
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dictates that particles with an aerodynamic diameter between 1-5m are deposited in the 
lower lungs, with larger particles impacting in the throat and smaller particles being 
exhaled. In reality there are a complex range of critical factors for efficient deposition of 
particles in the lungs including the size, density, shape, velocity, charge, hydroscopicity 
and surface properties of the particles as well as the breathing pattern of the patient (e.g. 
ventilation volume, flow rate, end-inspiratory breathholding)[13] and the state of the 
respiratory system including the patients age, sex, anatomy, lung volume and disease 
state[14]. Recent advances in inhaler/nebuliser device design [1518]  and therapeutic 
aerosol bioengineering (TAB) [19] means that improved delivery efficiencies can now be 
achieved in the context of optimised formulations and breathing patterns for a given 
device. This is of particular importance for systemic delivery of drug molecules when 
absorption is site-specific and also for expensive biotherapeutics, where poor delivery 
efficiency would make therapy prohibitively expensive.  
 
The alveolar epithelial cells and not the underlying endothelial cells are the major barrier 
to transport [20]. Though the alveolar epithelium is highly permeable to water, gases, and 
lipophilic substances, the permeability of large, hydrophilic substances, such as proteins 
is limited [21].  The non-absorptive clearance processes of the lungs are another hurdle to 
systemic delivery and can have a major impact on the amount of active drug available for 
transport across the mucosa. The role of mucociliary clearance in the tracheobronchial 
tree is to remove unwanted irritant particles from the lung, therefore insoluble drugs 
and/or insoluble delivery systems deposited in the upper airways are rapidly cleared [22]. 
Insoluble drugs and carriers deposited in the alveolar region will tend to be taken up by 
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the macrophages, which has recently been demonstrated to pose a primary barrier to 
pulmonary absorption of macromolecules [23]. They can dispose of particles either by 
transporting them along the alveolar surface to the mucociliary escalator, by translocation 
to the tracheobronchial lymph or by internal enzymatic degradation [24]. In the case of 
protein and peptide drugs this can mean rapid degradation in the lysosomal system. Drug 
metabolising enzymes are present in much lower concentrations in the lungs [25] than in 
the gastrointestinal tract and the degree of drug metabolism appears to be drug-type 
dependent with small peptides being hydrolysed rapidly while for small molecules 
metabolism is minimal. A certain degree of metabolic clearance of insulin has been 
demonstrated in recent kinetic studies which would appear to impact on its <10% 
bioavailability in both human and animals alongside mucociliary clearance [26]. 
 
1.2 Drug candidates for systemic delivery via the lungs 
The majority of licensed topical drugs for inhalation have to-date been small molecules 
(-agonists, steroids, antibiotics etc.). While the potential of inhalation for delivery of 
biotherapeutics has gotten most of the press attention it is important not to overlook the 
advantages of this route for small molecule drug delivery to the systemic circulation. A 
number of small drug molecules appear to be viable candidates for systemic delivery via 
the lungs (Table 1). The rate of absorption of small molecules from the lungs is second 
only to intravenous delivery [5] and bioavailability tends to be higher than oral 
bioavailability. The main reasons for this is the decreased metabolic capacity in the lungs 
and the lower levels of drug efflux transporters expressed on the airway cells compared to 
the gastrointestinal epithelium. Just as for oral absorption the nature of the molecule 
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affects the rate of absorption with hydrophobic molecules displaying extremely rapid 
absorption in seconds to minutes while hydrophilic molecules tend to have a slightly 
longer half-life of about 60mintues [5]. Because of the very rapid onset of action of small 
molecules after inhalation it is thought that inhalation of the relevant small molecule 
could potentially be used to treat conditions such as seizures, arrhythmias and 
hypertensive crisis where speed is of the essence.  
 
Pulmonary peptide and protein delivery appears to be an increasingly viable option for 
their systemic delivery [7,27] with bioavailabilites surpassing routes such as transdermal, 
nasal and buccal.  Two proteins for inhalation are currently available on the market 
DNase (locally acting mucolytic for Cystic fibrosis) and now to the delight and relief of 
many working in the field, insulin. A wide range of other proteins and peptides for 
systemic delivery via the lungs are being investigated, including calcitonin, growth 
hormone, immunoglobulins, and granulocyte colony-stimulating factor (G-CSF) to name 
a few (Table 1) The advantages of this route for macromolecular delivery are well 
documented and recently reviewed [7,28,5,29,30], with the molecular weight of a given 
macromolecular drug candidate impacting significantly on the rate of absorption [31,32] 
and metabolism[7,5].   Despite its perceived potential, progress to market in the area of 
systemic delivery of proteins has been slow to-date due to a number of confounding 
factors including rapid clearance, instability [33], risks of immunogenicity [33] and long-
term toxicity, dosing issues[28] and limited additives licensed for inhalation. These issues 
have been covered in some detail in recent reviews [29,30]. 
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1.3 Strategies to enhance systemic drug delivery via the lungs 
A number of different approaches to improve and/or control systemic drug delivery via 
the lungs and overcome some of the barriers previously discussed are being investigated. 
These include improved delivery efficiency to the lower lungs, molecular engineering of 
the drug molecule itself and/or addition of various excipients to enhance absorption 
and/or retain the drug at the site of absorption (Table 2). 
 
To facilitate the delivery of expensive biotherapeutics as well as enhance systemic drug 
delivery a range of new generation devices have been engineered that produce much 
higher respirable doses. These include a new generation of liquid-spray devices [34,35] 
that generate an aerosol mechanically, vibrating mesh technologies [17] and dry powder 
inhalers that produce inhalable aerosols independent of the patients’ inspiratory flow rate 
and volume [36,18]. 
 
Altering the molecular structure of a drug can be used to alter its kinetics in the lungs 
with the obvious caveat of preserving the activity. Studies indicate that cationic and 
hydrophobic small molecules have a longer half-life in the lungs [27] and for small 
peptides the degradation rate in the lungs can be decreased by cyclising the peptide or 
modifying the C or N terminal ends to block peptidase attack. Modifying drugs, in 
particular peptides and proteins, with polyethylene glycol (PEG) [37,5] groups also 
increases retention in the lungs thereby increasing bioavailability after inhalation [38].  
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Various formulation approaches have been tried such as the use of penetration enhancers 
(decreasing the epithelial barrier) and enzyme inhibitors (decreasing the proteolytic 
barrier) [3941]. The application of both approaches has been limited, however, due to 
safety concerns but some success has been achieved with low molecular weight amino 
acid analogues[42]. Ligands that specifically trigger an active uptake process in the 
alveolar cells may be preferable from a safety perspective to generalized permeation 
enhancement that allows the non-specific passage of other particles across the airways. 
[11,43]. 
 
Bioengineering of therapeutic aerosols using carriers such as liposomes and microspheres 
have been assessed as a strategy to improve systemic absorption of drugs via the lungs 
[44]. Both liposomes [45,46] and microspheres [4749] have been used to enhance the 
systemic effect of insulin after inhalation. The concentration, charge and acyl chain 
length of the phospholipids components of liposomes are critical to their ability to 
enhance systemic delivery [46]. The beneficial effects of microspheres on systemic 
absorption are attributed to the sustained release of the insulin from the polymeric 
carriers [50]. Other strategies to decrease clearance and prolong mucosal drug exposure 
have employed bioadhesive polymers e.g. HPC [51].  
 
1.4 Ex-vivo models of drug absorption across the lungs 
While cell cultures are an increasingly important tool for preliminary studies of drug 
transport and drug transport mechanisms across airway cells, the potential permeation 
enhancing effects of excipients and for a preliminary assessment of the potential toxicity 
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of a drug/drug delivery system [52] there are limitations to their utility in absorption 
kinetic studies and in order to overcome some of these limitations ex vivo models of lung 
absorption have been developed. One of the most commonly used ex vivo methods is the 
isolated perfused lung model (IPRL). The lungs are isolated from the body of an animal 
(generally rats or guinea pigs) and housed in an artificial system under defined 
experimental conditions [53,54]. Peristaltic pumps carry perfusate (autologous blood or a 
buffered artificial medium equilibrated with a mixture of oxygen and carbon dioxide) to 
and from the organ which is housed at 37ºC and the system can be maintained at a 
specific pressure. Drugs/delivery systems are administered via the tracheal port. 
Sampling of the perfusate allows the rate of absorption of the drug to be determined. This 
ex vivo model offers a number of advantages over isolated cell culture models because of 
the maintenance of the structure and functionality of the tissue. 
 
Limitations of these models include short viable periods of 2–3 hours, the likely absence 
of tracheobronchial circulation and the high level of training and expertise required to 
set-up the IPRL. In spite of this ex vivo models have been shown to be kinetically 
predictive of in vivo with respect to certain molecules, most notably macromolecules. 
There appears to be a less certain correlation for small molecules. The reason for this 
would appear to be the absence of the tracheo bronchial circulation in this model. While 
large molecules are generally not absorbed in vivo across the thick tracheobronchial 
epithelia small molecules are, therefore the lack of circulation in this region in IPRL 
makes modeling their absorption difficult. Isolated tracheal tissues used ex vivo have 
been used to characterise tracheobronchial airway absorption when relevant.  
 13 
 
One of the advantages of these ex vivo models for the purposes of modeling in vivo 
absorption and clearance is of course the presence of a whole organ with the full range of 
cell types, this can however make assessing the mechanism of absorption more difficult. 
Nevertheless recent improvements in kinetic profiling have enabled the kinetics of not 
only passive and/or active absorption to be determined but also those of the kinetics of 
drug clearance from the lungs (including phagocytosis, mucociliary clearance and 
metabolism). Studies also indicate that the appearance of test molecules in the perfusate 
correlates well with the depth of aerosol penetration. Unfortunately because of the 
complexity and cost of the set-up and the limited throughput of this model its’ use to-date 
has been limited. 
 
Therefore in order to properly assess the feasibility of systemic drug delivery after 
inhalation and the effect of new device/molecular engineering/particle bioengineering 
strategies to improve absorption animal models are vital. The anatomical and 
physiological differences between species have to be taken into careful consideration as 
well as the method of delivery of the drugs.  
 
2. Animal Models  
Ideally, the evaluation of factors influencing the delivery of drugs across the airways 
should be conducted in healthy or diseased humans. Animal models, however, allow 
manipulation of the different variables involved that otherwise may not be easy or 
feasible in human subjects. A large number of studies have employed rodents, but other 
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animal models including rabbits, dogs, sheep, monkeys and non-human primates have 
also been used.  Recently, Sakagami [55] reviewed the in vivo, in vitro and ex-vivo 
models available to assess pulmonary absorption and disposition of inhaled therapeutics 
for systemic delivery. This article gives an excellent perspective on the available animal 
models and techniques. The present section extends to anatomical, physiological and 
technical considerations required for the selection of the species and method of aerosol 
administration involved in a particular study. 
 
Initial studies in virtually every area of pharmaceutical and pharmacological research 
have been performed in small rodents such as mice, rats and guinea pigs because terminal 
procedures can be easily conducted and large numbers of these animals can be used for 
statistical validity. Rats and guinea pigs are frequently used for the study of drug delivery 
to the lungs because a variety of dosing techniques that require a small amount of the 
drug can be employed and they are good models for a number of respiratory disease 
states. Studies of the comparative biology of the guinea pig have revealed that the 
physiology of their pulmonary tract is quite similar to that of humans, particularly the 
response of the lung to inflammatory stimuli as well as the dermal response to both acute 
and chronic inflammatory mediators [56,57]. Therefore guinea pigs are regarded as a 
good model of bronchoconstriction/ bronchodilation in the evaluation of drugs used to 
treat asthma. Hormonally and immunologically guinea pigs are more like humans than 
other rodents; thus they are often used to model human infectious diseases [58]. Although 
rats are not as similar to humans they have been used to study a range of diseases such as 
emphysema [59], influenza [60] and pulmonary fibrosis [61]. Other systemic diseases 
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such as diabetes can be induced in rats by administration of streptozocin [62]. Delivery of 
large doses of aerosol to mice is difficult to achieve in short periods of time and the 
amount of biological fluids that can be collected is small. Nevertheless, mice have been 
used to investigate drug delivery in disease states such as cystic fibrosis [63] and lung 
cancer [64]. 
 
The use of larger species such as rabbits, dogs, sheep and primates is considered when 
the study design is more complex, requiring more sophisticated maneuvers, 
administration of larger doses of drug or collection of larger amounts of body fluids for 
longer periods of time is required. However, regulatory agencies and cost may limit the 
number of animals employed in these studies, which in turn may influence the statistical 
analysis of the results. The dog model has been utilized to study the delivery of insulin 
[65] or the treatment of some allergies [66]; monkeys and non-human primates have been 
employed to assess vaccine delivery [67] or drugs to treat cystic fibrosis [68], where 
sheep are considered a good model of lung injury [69]. 
 
2.1 Rational model selection  
Although many species are suitable for studies of disposition of drugs, in and from the 
lungs, the organization of cells and tissues in the lung is an important consideration in the 
selection of an animal model when the results are to be extrapolated to humans. This is 
crucial when the quantitative description of airways may be used in mathematical models 
for predicting efficiencies of deposition and clearance of inhaled drugs. Comparisons of 
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the morphologic characteristics of the lungs of many mammalian species have been 
reported [70] and key differences in individual anatomical parts are discussed below. 
 
Some of the anatomical characteristics of the lungs for several species are compared to 
those of the human lungs in Table 3 as revealed on replica casts [70]. In overall shape, 
the human lung tends to be more spherical than the lungs of other species. The 
significance of overall shape is seen in the relatively symmetrical airway branching 
scheme at essentially all levels in the human compared with the long tapering 
monopodial airways with small lateral branches characteristic of all the other species. 
Tracheal length–to-diameter (L/D) ratios differ considerably among mammals as do the 
branching angles. The guinea pig and rabbit have relatively long tracheas; dog, monkey, 
rat and hamster are intermediate, while human is relatively short as compared to other 
mammals. In terms of the number of lobes, the left human lung is divided into two lobes, 
the superior and inferior, and the right lung is divided into three by the addition of a 
middle lobe. The right lungs from laboratory mammals including non-human primates 
are divided into four lobes. The left lungs from mice and rats are not divided but those 
from larger mammals such as guinea pigs and rabbits are divided [71]. Several studies 
have indicated that the variations in airway branching patterns and the consequent effects 
on airflow across species can contribute to differences in regional deposition in the 
lungs[72,73] but this must be seen in the context of other contributory factors e.g. 
differences in breathing patterns, obligate nose-breathing and the physics of the aerosols 
delivered[74]. Overall it would appear that the airway anatomy and oral breathing of 
humans tends to lead to a greater amount of upper bronchial airway particle deposition 
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and to greater deposition on localized surfaces near airway bifurcations compared to 
smaller mammals[75].  
 
Table 4 shows the morphometric characteristics of cells in the alveolar region of the 
lungs of rats, dogs, baboons and humans [76] . Compared with the other species, human 
lungs contain greater number of macrophages. Significant interspecies differences in 
diameter, volume, number and functionality have been reported between human, monkey 
and rats/hamsters alveolar macrophages [7780], which may have implications for 
effective clearance. The thickness of the interstitium and the pulmonary capillary 
endothelium of the human lungs were also significantly greater. In addition, turnover 
times for several cell populations in the lung are significantly different between species 
[81]. 
 
For respiratory mechanics, the same expressions are used for lung volumes in man and in 
other mammals, but the mechanics that define most of them are different [82]. Total lung 
capacity and residual volume are maximum and minimum volumes, achieved in co-
operative humans by voluntary maximum effort but in animals by application of external 
pressures whose magnitude and timing are not standardized. Marked variations are also 
present in the lung volume and breathing frequency of different species (Table 5). 
 
2.2. Comparative responses in the respiratory tract.   
In all types of inhalation studies, at least three aspects of exposure to aerosolized drugs 
should be considered: deposition, clearance and the magnitude and type of the biological 
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response. Staufer used dimensional analysis to predict that the probability of deposition 
of inhaled aerosols should be the same for different animals in the case of sedimentation 
or turbulence-dominated deposition, but should scale as (body weight)0.1 for a diffusion 
dominated deposition [83]. Conversely, McMahon et al. suggested that diffusion 
dominated deposition is independent of body weight [84]. Studies in six different species 
showed that when the total amount of aerosol deposited was divided by the animal’s body 
weight, the smaller animals had received more particles/g than the larger ones, but the 
collection efficiencies (fraction of inhaled aerosol deposited) for both the lungs alone and 
the lung, nose pharynx and airways combined were substantially independent of body 
size.  
 
The different rates of clearance among species can also influence retention and, therefore, 
the total dose to the lungs. Brain et al. demonstrated that in situ pulmonary macrophages 
of hamster cleared insoluble gold particles faster than rats, rabbits and mice [85]. 
Different species have also demonstrated varying degrees of efficiency in the bactericidal 
activity of alveolar macrophages [86]. Rabbit alveolar macrophages avidly ingest and kill 
S. aureus, whereas alveolar macrophages from rats ingest but are rather poor at killing the 
same organisms. Nguyen et al also reported significant differences in phagocytosis and 
killing by pulmonary macrophages from humans, rabbits, rats and hamsters [87]. The 
relative rates of deposition and clearance determine the amount of drug present in the 
respiratory tract, thus the species selected for testing will influence the resulting dose to 
the lungs.  
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Different species breathing the same aerosol do not receive identical doses. As outlined 
above, there are variations in ventilation, collection efficiency, lung anatomy and 
clearance mechanisms among species that influence the local doses of therapeutic 
aerosols. Varying biological responses to the same aerosolized drug also reflect 
differences in the activation, degradation, excretion or mechanism of action of the 
compound in each species. The innate responsiveness of the analogous cell, tissue, or 
organ may also vary among species. An example is the case of the antituberculosis drug 
isoniazid, which is well tolerated at doses of 100 mg/kg in monkeys, whereas in dogs, 
doses of 20 mg/kg produce convulsion, respiratory failure and death. For example, it has 
been found that monkeys almost completely acetylate (thus inactivate) isoniazid, while 
dogs do not have that capability [82]. 
 
2.3 Methods of Aerosol Administration 
The efficacy of an inhaled drug is influenced by the amount of drug deposited at the 
target site. However, care must be taken when interpreting and comparing aerosol 
delivery efficiency data. For example, studies may report the efficiency of delivery in 
terms of the delivered dose, but this parameter does not consider the fraction of the dose 
deposited in the periphery of the lung that is required to exert action locally or the 
absorbed dose as in the case of drugs intended for systemic action. Figure 1 illustrates the 
relative magnitude of the drug amounts relating to the delivered, deposited and absorbed 
dose compared to the total amount of drug that is placed in the device for delivery as well 
as some examples of techniques to quantify each of these parameters. 
 
 20 
The method of aerosol administration is a key factor in the design of animal studies for 
drug delivery to the lungs and will impact on the accuracy of the results obtained. 
Therapeutic compounds can be delivered to the lungs of animals by passive inhalation or 
direct administration methods that circumvent oropharyngeal deposition. Drug delivery 
of aerosols by passive inhalation in conscious animals is the most relevant method for 
extrapolating to therapy in humans. In inhalation toxicology there are methods to deliver 
accurate aerosol doses to conscious animals by passive inhalation [88], but their use to 
assess drug delivery may be impractical due to their complexity and the requirement of 
large reservoirs of drug, which are not relevant to small bolus doses. Direct 
administration methods are a good alternative, since a finite amount of material can be 
delivered to animals. However, since oropharyngeal and/or nasopharyngeal deposition 
are avoided in this approach the site of lung deposition is complicated by altered 
dependence on droplet or particle size effects compared with aerosol systems. Both 
methods of administration are discussed below. 
 
2.3.1 Direct administration methods 
The main advantages of direct administration are that small and relatively large doses of 
drug can be delivered by these methods and that the dose delivered can be accurately 
measured. The main disadvantage is that the use of these methods for multiple or 
consecutive dosing may not be recommendable since they are performed under 
anaesthesia, and the insertion of the device may cause local irritation. Direct 
administration methods include liquid instillation, spray instillation and dry powder 
insufflation, but only the last two deliver drug in a form proxy to true aerosol. In general, 
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they involve visualization of the trachea of the animal with the help of a laryngoscope to 
place a thin stainless steel tube in the trachea, near the carina, to administer drugs. For 
small rodents, the procedure is straight-forward but for large animals, including rabbits, 
dogs, pigs and monkeys, some surgical procedures such as tracheotomy may need to be 
performed to accommodate the device. 
 
Liquid instillation delivers drugs in the form of a liquid bolus. This method can cause 
significant stress in the subject, prevents uniform distribution throughout the lung and an 
unknown amount of the drug may be coughed up or swallowed. For spray instillation, the 
MicroSprayer™ (Penn Century, Philadelphia, PA) can be employed (Figure 2A). The 
atomizer in the tip of a long, thin, stainless steel tube generates a plume of liquid aerosol 
that can be deposited in the airways and deep lung. However, the droplet size is 
influenced by the physicochemical characteristics, such as viscosity of the 
solutions/suspension to be delivered.  The Dry Powder Insufflator™ (Penn Century, 
Philadelphia, PA) has a small chamber that can be filled manually with a small amount of 
dry powder (Figure 2B). The powder is then dispersed by applying small "puffs" of air to 
the device using an empty plastic syringe and the amount of sample delivered to the lungs 
can be determined by gravimetric analysis. The insufflator has been used to deliver 
different powders from nanoparticles [89] to large porous particles [90,91]. The 
physicochemical characteristics of the powder, including particle size distribution, as 
measured by a variety of techniques have been reported to be essentially unaffected by 
passage through the device [67,90,92,89,93,94]. However, the position of the device in 
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the trachea of the animal during powder delivery may affect the percentage of powder 
deposited in the different lung lobes [95]. 
 
A range of therapeutic compounds that have been administered to the lungs with direct 
administration devices include: antibiotics[9698], antiproteases [99,59,100], 
bronchodilators [101], chemotherapy [102,64], proteins and peptides [103105], lung 
surfactant [106], vaccines [60,107] and gene therapy [108,68]. 
 
2.3.2. Passive inhalation 
Experiments designed to deliver aerosolized drugs to conscious animals by passive 
inhalation employ exposure chambers that can be for whole body, head-only and nose-
only [88]. Each exposure type has its set of advantages and disadvantages. Advantages of 
the whole body inhalation systems include the ability to expose animals without restraint. 
The major disadvantage of these systems is the possibility of drug absorption by other 
routes including oral and percutaneous. A modified whole body exposure chamber was 
made using a conventional metabolism chamber with a polypropylene tube inserted to 
restrain the animal (Figure 3A) [109]. This chamber has the advantage of a small volume 
sufficient for the animal to receive a large dose of aerosol based on its inspiratory flow. 
Significant inter-individual variation might be anticipated as animals will vary in size, 
lung capacity and breathing parameters. Solution and suspension aerosols have been 
characterized and shown to retain the median particle size and distribution generated by 
the nebulizer after passing through the chamber [96,97]. Presumably this can be 
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attributed to the relatively small volume of the chamber and reduced tendency to lose 
particles by impaction and sedimentation [82]. 
 
The main advantage of head-only and nose-only exposure systems is the reduction or 
elimination of multiple exposure routes. Major disadvantages include adequate exposure 
seals for the face or neck of the animal and stress related to the restraint necessary for 
these studies [88]. Many types of nose-only exposure chambers are commercially 
available, including but not limited to those manufactured by CH Technologies 
(Westwood, NJ), Intox Products (Edgewood, NM), TSE GmbH (Badhamburg, Germany) 
and ADG Developments (Herts, UK). The exposure chamber manufactured by ADG 
(Figure 3B) is designed to deliver aerosols to approximately twenty rodents. Aerosols are 
continuously generated at a known concentration on a carrier air supply. Providing the 
mass flow (dose rate) and particle size and distribution remain constant each animal will 
be exposed to the same aerosol and the dose can be calculated from their respiratory flow 
parameters (tidal volume and breathing frequency). However, the inter-animal variation 
will play a role in dosing and it will still be necessary to independently evaluate the dose 
to the animal. This may involve conducting pharmacokinetic studies and inferring the 
dose or using in-vitro methods to estimate the dose at a given sampling flow rate. 
Aerosols of rifampicin solutions and suspensions of biodegradable particles have been 
delivered by this chamber for the treatment of tuberculosis [110,98]. 
 
Although contract research organizations conducting inhalation toxicology studies may 
use all forms of aerosol delivery devices (dry powder inhalers, pMDIs and nebulizers), 
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most published studies conducted with passive inhalation methods have employed 
nebulization to deliver drugs into the exposure chamber. A major limitation for the 
delivery of particles insoluble in biologically-friendly media by nebulization is the 
concentration that can be achieved in the suspension. Nebulization of highly concentrated 
suspensions may result in particle precipitation in the nebulizer and the delivery of very 
diluted aerosols. A new system for the delivery of powders to animals has been designed, 
the dry powder dispersion chamber [111]. The design is similar to that of the nose-only 
exposure chamber; however, the volume of the chamber is smaller and no air is 
introduced for the dispersion of powders in order to achieve a highly concentrated 
standing cloud of the therapeutic powder. This chamber has been used in 
pharmacokinetic and pharmacodynamic studies to deliver capreomycin for the treatment 
of tuberculosis in guinea pigs [111]. 
 
3. Methods to assess disposition and absorption of inhaled drugs 
Methods of aerosol characterization that can estimate the delivered dose in vitro have 
been widely described in the literature and are discussed later. Animal models employed 
to determine deposited dose and absorbed doses in vivo are discussed in this section. In 
general, these methods have been limited by the lack of sensitivity in the analytical 
procedures for the quantification of small concentrations of inhaled drugs in biological 
fluids and/or tissues.  
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3.1 Determination of local and systemic drug concentrations 
Once the drug has been delivered to the lungs, it is quantified by various methods 
depending on its desired effect.  
 
In studies involving delivery of drugs for local action, determination of drug 
concentrations in the lung environment (epithelial lining fluid and tissue) together with 
plasma concentrations provide more valuable information. However, since the procedure 
is terminal for most animal models, large numbers of subjects are required making these 
studies costly and complicated by regulatory issues.  
 
Bronchoalveolar lavage (BAL) is the sampling of the lower respiratory tracts by 
instillation of sterile saline and subsequent aspiration of the fluid [112]. Quantification of 
the drug in BAL can estimate concentrations in the epithelial lining fluid. The technique 
recovers cells, soluble proteins, lipids, and other chemical constituents from the epithelial 
surface of the lung. In human subjects BAL is performed under mild sedation. A flexible 
fiberoptic bronchoscope is employed to pass as far as possible in the right middle lobe or 
left upper lobe of the lung. Normal saline solution is introduced and aspirated. Then, the 
aspirated fluid is collected and analyzed. In large laboratory animals such as dogs and 
nonhuman primates, in vivo BAL is performed in a manner similar to that used in 
humans. BAL of small laboratory animals can be performed in vivo if required [113], but 
most lavage of rodents are performed on excised lungs. A catheter inserted into the 
trachea is used to instill the saline solution. Lavage volumes also vary for small 
laboratory animals, but usually the lavage volumes are approximately half of the total 
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lung capacity of the section of the lung lavaged. To evaluate drug concentration in BAL, 
two to four lavages might be performed to avoid excessive dilution of the drug. The 
concentration of urea in the BAL can be used as an endogenous marker [114] to estimate 
the sample dilution and accurately determine drug concentrations.  
 
Quantification of the drug in lung tissue can also be performed, but may be challenging 
due to complicated extraction procedures that may compromise the integrity of the drug. 
Determination of drug concentrations in tissue may also provide information on drug 
metabolism in the lung, such as those reported for insulin [115]. 
 
For drugs intended for systemic action, concentrations are determined in serum or 
plasma. The blood collection sites are determined based on the volume and frequency of 
sampling required. In pharmacokinetic studies conducted in small rodents that require 
frequent blood sampling for a short period of time (usually less than a week), 
implantation of a cannula in the jugular vein is recommended. This requires a relatively 
complex surgical procedure. For studies that require less frequent sampling, localized 
bleeding in tail vein or artery, saphenous vein and the dorsal metatarsal vein can be used 
[116]. In rabbits, the central ear artery and marginal ear veins are commonly used [116]. 
In large animals, blood may be collected from a superficial implanted catheter from the 
femoral, cephalic or jugular veins [117,118]. Some studies have also been conducted in 
animals using jugular venipuncture [119122]. However, the number of these studies may 
be limited by regulatory issues. 
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3.2 Pharmacokinetics models for the disposition of drugs in the lungs  
The pharmacokinetics of drugs after pulmonary delivery depends upon the dynamic 
interaction of different factors such as the site of deposition, clearance mechanisms, drug 
formulation (solid or liquid), dissolution rate,  drug metabolism and mechanism of 
absorption [123]. In animals as in human subjects, the factors that will influence drug 
deposition are particle shape, size and distribution, hygroscopicity, static charge, anatomy 
of the airways and breathing patterns such as frequency and tidal volume. However, as 
reviewed in previous paragraphs, the two latter factors are different in animals, thus, 
different deposition patterns should be expected in the different animal species that may 
influence the pharmacokinetics of drugs. Clearance mechanisms include mucociliary 
clearance and endocytosis. Large interspecies differences have been reported in the lung 
clearance of inhaled particles [124,125]. However, lung models have been developed to 
extrapolate between different species [126]. Studies have also shown that the transport of 
particles by macrophages to the larynx that is substantial in rodents is rather small in 
humans [127]. Extensive reviews have been published on mechanisms of drug absorption 
in the lungs [128,129,6,130,9,10,131,12], thus they will not be included here.  
 
Few models have been proposed to address lung residence time of soluble aerosols, due 
to the complexity of the processes involved and the factors that affect these. Byron [132] 
developed a mathematical method to determine residence times in the various regions of 
the respiratory tract as well as maximum deposition in these regions based on 
optimization of modes of inhalation and particle size. However, this model does not 
differentiate between drug released (pharmacologically active) and unreleased drug nor 
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does it separate absorption rate from dissolution rate. Therefore, Gonda [133] proposed a 
compartmental model that simulated the effects of release rate and multiple dosing on the 
duration of ‘free drug levels’ in the respiratory tract. This model also accounts for the 
possibility of accumulation of carrier materials during chronic administration as a 
function of drug release rate. 
 
Pharmacokinetic (PK) parameters after aerosol administration of a drug can be calculated 
using compartmental or non-compartmental methods, and recently physiologically based 
PK models are being used more.  
 
Compartmental methods consider the body as a system of compartments that usually are 
not physiologically or anatomically significant and determines the drug distribution 
between these compartments [134]. Compartments are arranged in a mammillary model 
and evaluated by intercompartmental transfer constants that assume instantaneous 
distribution. It is assumed that the rate of transfer between compartments and the rate of 
elimination of drug from a compartment follow first order or linear kinetics. The criteria 
to determine the best fitting model to a specific set of data are the Akaike criteria, the 
model selection criteria (MSC), the coefficient of variation (CV%), and the width of the 
confidence interval for each parameter estimate. The systemic disposition of most inhaled 
drugs is best characterized by one or two compartment models. The disposition of a few 
drugs has been characterized by a three compartment model with central elimination 
[135,123].  
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Noncompartmental methods consider a central homogeneous space, where drug input and 
elimination occur, and a heterogeneous space [135]. Drug is also sampled in the central 
space and the change of drug concentration over time in this space is usually regarded as 
a statistical distribution curve [136]. These methods are usually based on the estimation 
of the area under the drug concentration-time profile. Clearance, bioavailability, mean 
residence time and mean absorption time can be calculated by this method. 
 
The main contribution of physiologically based pharmacokinetic methods is that they 
allow the prediction of drug concentrations in tissues in which samples cannot be easily 
collected. These models are well suited for making high-low dose, dose route and 
interspecies extrapolations by incorporating quantitative descriptions of the physiological 
and biochemical processes of the animal and the biochemical properties of the drug 
[123]. A classical PBPK consists of different compartments with each representing a 
particular organ. The organs of interest are selected based on different factors such as the 
route of administration of the drug, extent of body distribution, binding characteristics, 
elimination pathways, and pharmacodynamic activity. 
 
3.3 Methods to calculate the rate of absorption and pulmonary bioavailability 
The rate of absorption has been determined by measuring the disappearance of drugs 
from the lungs or their appearance in systemic circulation. The rate of absorption is then 
calculated after curve fitting of semilogarithmic plots of the % remaining in the lung 
versus time or drug concentration over time [137]. The estimation of pulmonary rate of 
absorption is complicated by different situations such as gastrointestinal absorption of 
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drug swallowed following pulmonary administration, lack of sensitive methods to detect 
relatively small plasma and urine drug concentrations achieved under these circumstances 
and pulmonary metabolism.  
 
The three methods most commonly used to estimate the rate and extent of absorption are 
the Wagner-Nelson, the Loo-Riegelman and the observational methods. The first two are 
based on curve fitting by compartmental analysis whereas the observational method is 
based on non-compartmental analysis [134,135]. The most important limitation of the 
Wagner Nelson method is that it is applied exclusively to drugs with one compartment 
disposition [138]. Loo-Riegelman proposed a modification in which the amounts of drugs 
absorbed at specific times could be calculated using two-compartment body models with 
first order elimination processes [139]. An inherent limitation of this method to determine 
pulmonary absorption is the intra-subject variability in inter-compartmental transfer 
constants between intravenous and pulmonary administration. The observational method 
is the most simple and practical method. Cmax and Tmax parameters, obtained directly from 
drug concentration versus time plots, are used to determine the rate of absorption. Cmax 
depends on both the rate and extent of absorption while Tmax takes discrete values and 
may be subject to reliability problems because its frequency is not normally distributed. 
Alternative measures include Cmax/AUC∞, Cmax/Tmax, Cmax/AUCmax [135]. 
 
Caution should be exerted when interpreting the constant of absorption calculated for a 
drug delivered by the pulmonary route, since some characteristics of the drug, such as 
physical state (solid or liquid), solubility and possible interactions with excipients or 
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carriers can influence this parameter. For example, if the rate of drug absorption is 
limited by its poor solubility in the lung environment, the constant of absorption may be 
underestimated. Slow drug absorption may in turn influence the rate of elimination. This 
situation is known as flip-flop kinetics [136] and has been observed for tobramycin [140] 
and insulin [26]. Likewise, estimation of the rate of drug absorption from the lungs 
simply on the basis of Tmax is not recommended, since a short systemic half life can 
influence the magnitude of Tmax. 
 
Differences in the rates of absorption have been observed among different species for 
hydrophilic drugs [141]. These compounds were absorbed 5 times faster in the mouse 
than in the rat, and 2.5 more slowly in rabbits than in rats. Conversely, lipophilic drugs 
were absorbed at the same rate in all species. 
 
The term bioavailability describes the rate and extent of drug absorption. Methods for 
assessing bioavailability of drugs in the lungs are limited by analytical issues related to 
the low drug concentrations in lung tissue and plasma after aerosol administration. For 
some drugs such as β2-agonists the issue of low plasma concentration can be 
circumvented by measuring drug in urine [142]. Oral charcoal has also been used to 
prevent GI absorption of drug that is swallowed after inhalation [143,144]. 
Complementary techniques such as imaging (discussed below) can be also used to 
estimate drug bioavailability. Pulmonary bioavailability can be calculated using AUCs 
after IV and pulmonary administration using the following equation.  
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It is important to note that the accurate pulmonary dose should be used in this calculation 
to avoid overestimation of bioavailability. Thus, direct methods of administration, in 
which the dose can be accurately measured, should be employed for this purpose. 
Interpretation of bioavailability values in animals should be made with caution, since 
depending on the species selected, this parameter could be overestimated or 
underestimated in humans. Pulmonary bioavailability of insulin is underestimated in rats 
and overestimated in rabbits and monkeys when compared to that of humans [145]. 
Although it is likely that factors such as differences in airway morphology and clearance 
mechanisms may have contributed to differences in insulin bioavailability in these 
species, the dosing techniques employed may have played a larger role. In the case of the 
rat studies [146] bioavailability may have been underestimated because intratracheal 
instillation was employed for dosing, most likely covering less than 5% of the lung 
surface, whereas in the rabbit and monkey studies [147,148] bioavailability may have 
been overestimated since a larger surface area is reached by nebulization. 
 
When no analytical method can determine tissue or plasma drug concentrations, the 
magnitude of its effects (pharmacodynamics, PD) can be quantified to assess drug 
absorption. PD can be defined as the study of the biological effects and their mechanism 
of action. The objectives of the analysis of drug action are to delineate the chemical or 
physical interactions between a drug and the target cell and to characterize the full 
sequence and scope of actions of each drug [136]. Studies that evaluate the disposition of 
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insulin formulations for inhalation have employed drug pharmacodynamics as a measure 
of aerosol disposition [103,105]. These studies measured the decrease in glucose levels 
after administration of insulin formulations. The reduction of bacterial burden in affected 
organs after aerosol administration has also been used to assess the pulmonary disposition 
of anti-tubercular drugs [96,97,91,111]. 
 
3.4 Imaging of drug deposition and absorption 
Imaging is an exciting tool in drug development and its’ role in the assessment of drug 
delivery is growing. With the improvements in imaging technology it is now possible to 
determine the delivery efficiency of a drug to its site of action and the resulting 
pharmacokinetics. Being able to characterise these parameters using non-invasive 
imaging of whole animals is particularly useful for assessment of inhalation delivery 
systems given the complex anatomy of the lungs and the complex biophysics governing 
aerosol deposition.  
 
Drug distribution and kinetics of inhaled drugs in human lungs are primarily assessed by 
the imaging of radiotracers. Gamma scintigraphy is the most commonly used imaging 
method but single photon emission computed tomography (SPECT) and positron 
emission tomography (PET) are growing in popularity [149,150]. In general terms two 
major approaches have been adopted for imaging small animals: the first is the adaptation 
of clinical imaging technologies such as gamma scintigraphy, SPECT (Figure 4) [151]  
and PET to the smaller animal dimensions and the second is based on new evolving 
technologies based on whole-body photonic imaging[152]. 
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A number of studies have used nuclear imaging to image radiolabelled drugs and 
particles delivered to small [153] and more commonly large [154,151,155158] animals. 
Gamma scintigraphy has long been a mainstay of human lung studies and it could play a 
key role in the fundamental assessment of the effects of different devices/formulations on 
drug deposition and clearance in the lungs affecting drug absorption. There are 
difficulties and limitations to its use that include a need for careful validation of the tracer 
and potential problems in trying to quantify distribution with what is essentially a non-
quantitative technique[150]. The capabilities of and technology behind human scanning 
have improved greatly over recent years, particularly with the emergence of SPECT and 
PET scans. SPECT is essentially planar imaging with a different gamma camera. In 
essence, planar images are acquired from several different angles and used to construct a 
3-D distribution of radioactivity within the lungs (Figure 4) and clinically is becoming 
more popular than planar imaging, due to the improved data quality from both a 
qualitative and quantitative perspective. The disadvantages of this technique include the 
extra time to complete a scan and labelling of the drug of interest[150]. PET is a 3D 
functional imaging technique that provides accurate information on dose, distribution and 
kinetics of an inhaled radiotracer in the lungs[159]. This technique used to assess drug 
delivery to animals would provide a wealth of additional information including more 
accurate images detailing the regional distribution of the drug in the lungs, in vivo 
estimation of large airway/small airway deposition and functional imaging of physiologic 
and biologic processes in vivo [160]. The major advantage of PET is its high sensitivity 
without the penetration limitations of optical techniques. The most obvious limitations of 
this technique are the cost and complexity including the requirement for a local cyclotron 
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to generate probes, developing a labelling method for the drug in question, data analysis 
of complex studies and limits to quantification accuracy due to camera spatial resolution 
[150]. 
  
Another exciting new technology to study drug deposition and absorption through the 
lungs is real time in vivo fluorescence imaging. Temporal and spatial data can be 
collected from the same animal over multiple time-points allowing a real-time collection 
of data with significantly decreased animal numbers using drugs labelled with a 
fluorescent molecule such as a dye or quantum dot in whole-body living small animals 
[161]. It is a technique which is gaining increasing popularity amongst biological 
scientists but which could have enormous potential in drug and drug delivery system 
biodistribution studies going into the future [162]. Its comparative usefulness in 
inhalation PK studies has yet to be established. 
 
4. Inhalation Toxicology in Animals: 
With a growing number of candidate drugs (Table 1) and additives being assessed for 
drug delivery across the lungs (Table 2) animal models have a further fundamental role in 
inhalation toxicology. The main focus of inhalation toxicity studies is to determine local 
toxicities and evaluate the extent of systemic toxicity [163]. Inhaled substances can 
potentially have a range of deleterious effects from subtle changes in respiratory function, 
alterations in lung biochemistry and permeability to immunogenic effects and potentially 
mortality. The presence of enzymes in the lungs can also present the risk of toxic drug 
metabolites being formed after inhalation [164]. 
 36 
 
Choice of animal species is equally important for toxicological as pharmacological 
testing and the choice of animal models for inhalation toxicity testing is influenced by a 
number of factors including guideline requirements and practical considerations, such as 
exposure technology, expediency, previous experience [165] and differences in biological 
responses. Different species having different biological responses as exemplified by the 
varied reactions of monkeys and dogs to isoniazid outlined in section 2.2. and this 
impacts on the relevance of extrapolation of toxicity data to humans. Boyd and Neal 
showed that the LD50 of Alpha-naphthylthiourea (ANTU) varied by more than two orders 
of magnitude between species when rodents, rabbits, dogs, cats, chickens and monkeys 
were compared [166]. These varying biological responses can be due to differences in 
deposition and clearance as well as differences in the activation, degradation, excretion, 
or mechanism of action of the substance in a given species[82]. There can also be animal 
specific factors that impact on the degree of exposure of the animal to the test substance. 
For example in rodents protective reflex reactions can limit exposure of the animal to the 
test substance being investigated [167]. 
  
Bolus doses of aerosol can be delivered to large animals such as dogs, pigs, sheep or 
primates from conventional inhalers but it is more likely that the early toxicological tests 
will be carried out in rodents. For rodents, spray instillation or powder insufflation is 
preferred to allow uniform dispersal of a defined dose in the lungs, to be followed by 
aerosol studies should the results prove positive. When conducting inhalation studies 
nose-only exposure is preferable to whole-body modes of exposure due to improved dose 
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control. Care must be taken in selection of the exposure system to minimize stress on the 
animals which can lead to artifacts [167]. Just as for PK/PD studies innate species 
differences such as: obligate nose breathing, differences in anatomical sizes, geometry 
and pulmonary function can lead to order of magnitude differences in upper respiratory 
deposition and consequently lung delivery. Accurate dose determination based on factors 
such as body weight, minute volume, percentage deposition, retention and absorption and 
pulmonary and extrapulmonary pathomechanisms[168] is essential as nominal dose can 
differ greatly from the actual dose delivered. In terms of extrapolation to humans the 
upper bound for the initial dose for a Phase 1 clinical trial is generally a fraction of the 
no-observed-adverse-effect level (NOAEL) in animals[163] but again the specific 
fraction is species dependent. 
 
Indicators of toxicity can include changes in haematological, biochemical, neurological, 
physiological, immunological and exposure-related morphological effects, morbidity and 
mortality. The main focus of early stage acute preclinical studies designed to determine 
the feasibility of inhalation as a route of administration for an existing or new drug entity 
would be on local effects (as systemic effects would be unlikely after such short term 
exposure) and would include an assessment of pathological changes, inflammation and 
gross effects, which could potentially manifest themselves in the animal’s behaviour [82]. 
Other markers of toxicity would include the wet and dry lung weights to evaluate fluid 
ingress into the lungs, histopathology to evaluate damage to lungs and cellular infiltration 
(monocytes, lymphocytes, polymorphonuclear cells). Even if such gross toxicity is not 
evident after only a single dose or small number of doses then it may be possible to 
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identify more subtle toxicological changes. Pulmonary function testing can identify 
changes in breathing parameters and analysis of the airway fluid using BAL (as described 
in section 3.1) can provide more subtle early markers of toxicity. BAL can be studied for 
changes in cell numbers and the presence of enzymes indicative of cell damage, e.g. 
lactate dehydrogenase, as well as the levels of inflammatory cytokines, e.g. interleukins, 
and reactive intermediates, e.g. nitric oxide. BAL can also be used to assess changes in 
airway permeability by determining the serum protein concentration in the lungs. Inhaled 
substances can affect the epithelial barrier by opening tight junctions or increasing cell 
membrane permeability. Immunological changes effected by inhaled substances can 
include local inflammation, bronchoconstriction, hypersensitivity and more damaging 
pathological changes such as basement membrane thickening all of which can impact on 
existing respiratory diseases and potentially underly progression to long-term disease 
states[82]. 
 
A full toxicological program involves acute inhalation toxicity testing, subchronic and 
chronic toxicity testing [82]. The main objective of acute inhalation toxicity is to 
determine the gross pathology and histopathology resulting from acute inhalation 
exposure to a drug but as described above monitoring of more subtle biochemical, 
physiological or immunological changes may prove useful at this stage of 
development[82]. In a sub-chronic exposure study the adverse effects resulting from 
repeated daily exposure of experimental animals to a chemical by inhalation for 
approximately 10% of their lifespan is determined. For mice this translates to exposure 
for 6hrs/day, 7 days a week for 18months, while for rats exposure is for 6hrs/day, 7 days 
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a week for 24months. In a chronic exposure study the effects of a drug in a mammalian 
species following prolonged and repeated exposure are determined and effects that 
require a long latency period or are cumulative can be assessed. Other testing required 
can include hypersensitivity testing, carcinogenicity testing, reproductive toxicity studies 
and paediatric testing depending on the duration of treatment, target population etc. 
[163]. A detailed description of inhalation toxicity studies including respiratory 
physiology assessment, histopathology and bioassays  is beyond the scope of this review 
but several comprehensive reviews are published [169171,82,172]. 
 
There are a very limited number of excipients currently licensed for inhalation and a 
dearth of toxicological data which limits the range of formulation strategies that can be 
employed to enhance drug delivery and potentially absorption in a clinical setting. 
Improved toxicological assessment of such excipients could only benefit the field. A 
good example of such studies, were those conducted on HFA-134a as an alternative to 
chlorofluorocarbons for use in metred dose inhalers. Comprehensive preclinical 
inhalation toxicology study results indicated that HFA-134a was not considered toxic or 
oncogenic [173,174] and appeared to have no reproductive toxicity[175] and was 
therefore deemed a safe alternative. The potential of the lungs as a route of systemic 
administration of a drug will largely be determined by the toxicological implications of 
its inhalation and therefore good study design is critical. 
   
5. Conclusion 
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Comprehensive characterisation of drug delivery to the lungs is a complex task involving 
determination of delivered, deposited and for systemically targeted drugs absorbed dose. 
There is great scope for improved in vitro simulation of in vivo disposition and absorption 
of drug molecules after delivery to the lungs but in order to properly assess the 
pharmacokinetics effective use of animal models is still essential. This is particularly true 
for systemic delivery across the lung mucosa where the impact of normal lung perfusion, 
the complete epithelial barrier and clearance mechanisms are significant and can only be 
modeled in whole animals. With the range of drugs being assessed for systemic delivery 
via the lungs increasing and a vast array of new excipients and technologies being 
developed to assist drug absorption across the airway mucosa there is a growing need for 
assessment of toxicity and immunogenicity of inhaled drugs/ drug delivery systems. This 
is another important role of in vivo animal models. Using the appropriate toxicological 
techniques any structural, biochemical and immunological changes in the lungs after 
short and long-term drug administration must be assessed.  
  
Great care must always be taken in rational animal study design but this is particularly 
true for pulmonary delivery. Because of the complexities and interspecies anatomical 
differences in the lungs it can be difficult to simulate the clinical situation of a human 
inhaling a drug. Appropriate choice of species and drug delivery method is therefore 
paramount. New devices designed specifically for inhalation animal studies and more 
sophisticated methods to determine drug deposition and absorption after inhalation are 
improving the information now derived from animal studies and hopefully reducing the 
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numbers of animals that will need to be used in the path to clinical development of drugs 
for systemic delivery via the lungs.  
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Tables: 
Table 1: Examples of drugs being investigated for systemic delivery via inhalation 
Drug candidate Indication Clinical 
status 
References 
Small molecules 
Amikacin Pneumonia Phase II [176] 
Amphotericin B Bronchopulmonary 
fungal infection 
Phase III [177] 
Apomorphine Erectile Dysfunction Phase IIa [178] 
Epinephrine Anaphylaxis Phase I [179] 
Fentanyl Pain Phase IIb [180] 
Iloprost Heart transplantation Phase III [181] 
Nitroglycerine Pulmonary hypertension Phase II [182] 
Nitric Oxide adducts Pulmonary hypertension Phase II [183] 
Ribavirin Viral infections Approved* [184] 
Sumatriptan Migraine Preclinical [185] 
THC (Dronabinol) Multiple Schlerosis, 
migraine, cancer, HIV 
Phase II [186] 
Prochlorperazine Migraine Phase II [187] 
Treprostinil Pulmonary hypertension Phase II [188] 
Proteins/Peptides 
Insulin Diabetes Approved [189] 
Cetrorelix LHRH antagonist Preclinical [190] 
Cyclosporin Immunosuppression Phase 0 [191] 
Follicle stimulating 
hormone 
Fertility treatment Preclinical [192] 
Parathyroid hormone Osteoporosis Preclinical [193] 
Heparin Prevention of thrombosis Preclinical [194] 
Calcitonin Osteoporosis Preclinical [195] 
Colony stimulating 
factorseg.Sargramostim 
Metastatic cancer, 
Sarcoma 
Phase II [196] 
Erythropoeitin Anaemia Preclinical [43] 
Glucagon like peptide  
(GLP-1) 
Diabetes Phase I [197] 
Human recombinant 
F.IX 
Hemophilia B Preclinical [198] 
Immunoglobulin Trigger/modulate 
immune response 
Preclinical [199] 
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Interferon-beta Multiple sclerosis Preclinical [200] 
LH-RH analogues Endometriosis, prostate 
cancer 
Preclinical [201] 
* only for hospitalized infants with Respiratory Synctial Virus infection 
 
 
 
Table 2: Strategies for enhancing systemic drug delivery via the lungs 
Strategy Principle Clinical Status Reference 
New generation inhaler 
devices 
Improved delivery 
efficiency to site of 
absorption 
Device 
dependant 
[1517,36,18] 
Molecular engineering: 
Modified peptides 
 
 
 
PEGylation 
 
Chemical modification of 
peptide of interest to 
protect it from lung 
peptidases. 
Reduce macrophage 
recognition and 
subsequent proteolysis by 
conjugation of 
drug/protein with PEG.   
 
Preclinical 
 
 
 
Preclinical 
 
[7] 
 
 
 
[202] 
Absorption promoting 
agents: 
e.g. Alkylglycosides, 
surfactants, bile salts, 
cyclodextrins, lipids and 
liposomes, amino acid 
analogues, carobopol, 
chitosan, protease 
inhibitors, dendrimers 
Reduction in epithelial 
barrier to absorption 
 
 
 
 
 
Phase II 
(liposomes) 
Preclinical (all 
others) 
[42] 
[193,203209] 
 
 
 
Bioadhesive polymers Prolonged drug exposure 
to the mucosa 
Preclinical [51,207] 
Bioengineering: 
Microparticles for 
inhalation composed of 
drug alone or 
with a range of excipients 
including PLGA, gelatin, 
albumin, PEG, sodium 
hyaluronate,  
 
Diketopiperazine 
derivatives 
(Technosphere™), 
 
 
Allow control over 
aerodynamic parameters 
and release of drug 
 
 
 
 
 
 
 
 
 
 
Preclinical 
 
 
 
 
 
 
 
Phase III 
 
 
 
 
[49], 
[210,48,21121
3] 
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Preparation of large 
porous particles 
Particle phagocytosis 
diminishes with 
increasing particle size 
Phase 0 
(Pulmosphere™) 
Phase III (AIR®) 
 
[47] 
Ligand targeting 
Drug conjugation to Fc 
domain of IgG 
 
 
 
 
 
 
Caveolae specific carriers 
 
 
Conjugation of proteins 
to the constant Fc region 
of antibodies enhances 
absorption in the airways 
since airways are 
enriched with antibody 
transcytosis receptor 
mechanisms. 
Conjugating the drug of 
interest to a 
protein/antibody which is 
transported in vivo via 
caveolae mediated 
transcytosis 
 
Phase I 
 
 
 
 
 
 
 
Preclinical 
[214,192,215] 
 
 
 
 
 
 
 
 
[11] 
Decreasing protein dose 
. 
Decreasing protein dose 
favors systemic 
absorption relative to 
local degradation 
Preclinical [23]. 
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Table 3: Comparative Airway Structure: from replica casts (modified from [76]) 
Animal 
 
Body 
mass 
Airway 
branching 
Trachea 
L/D(cm) 
Tracheal 
bronchus 
Major airway 
bifurcations 
Airway 
L/D 
(ratio) 
Typical 
number of 
branches 
to 
terminal 
bronchiole
s 
Human 80kg Relatively 
symmetric 
12/2 Extremely 
rare 
Sharp for about 
the first 10 
generations;rela
tively blunt 
thereafter 
2.2 14-17 
Laborat
ory rat 
0.3kg Strongly 
monopodial 
2.3/0.26 Rare Very sharp and 
very high 
throughout the 
lung 
1.5 12-20 
Guinea 
pig 
1kg Monopodial 5.7/0.4 Absent Very sharp and 
high 
1.7  
Rabbit 4.5kg Strongly 
monopodial 
6/0.5 Absent Sharp 1.9  
Beagle 
dog 
10kg Srongly 
monopodial 
17/1.6 Absent Blunt tracheal 
bifurcation 
1.3 15-22 
Rhesus 
monkey 
2kg Monopodial 3/0.3 Absent Mixed blunt and 
sharp 
2.6  
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Table 4: Morphometric parameters in the alveolar region of normal mammalian lungs 
(modified from [76] 
 Fischer 344 Rat  
Dog 
 
Baboon 
 
Human 
Body weight, kg 0.29  0.01 16  3 29  3 79  4 
Lung volume, ml 8.6  0.31 1322  64 2393  100 4341  284 
Total number of 
cells/lung, 109 
0.67  0.02 114  13 99  9 230  25 
Total lung cells, % 
   Alveolar Type I 8.1  0.3 12.5  1.7 11.8  0.6 8.3  0.6 
   Alveolar type II 12.1  0.7 11.8  0.06 7.7  1.0 15.9  0.8 
   Endothelial 51.1  1.7 45.7  0.8 36.3  2.4 30.2  2.4 
   Interstitial 24.4  0.7 26.6  0.7 41.8  2.7 36.1  1.0 
   Macrophage 4.3  1.0 3.4  0.6 2.3  0.7 9.4  2.2 
Average cell surface area, µm2 
   Alveolar Type I 7287  755 3794  487 4004  383 5098  659 
   Alveolar type II 185  56 107  15 285  85 183  14 
   Endothelial 1121  95 1137  127 1040  209 1353  67 
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Table 5: Tidal volumes and breathing frequencies among laboratory animals (modified 
from [216]). 
 
 
Species 
Respiratory rate 
(breaths/min) 
Tidal volume 
(ml) 
Minute 
volume 
(liters) 
Mouse 163 0.15 0.023 
Rat 85 1.5 0.10 
Guinea  Pig 90 1.8 0.16 
Rabbit 46 21.0 1.07 
Dog 18 320.0 5.2 
Monkey (rhesus) 40 21.0 0.86 
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Figure Legends: 
Figure 1: Relative magnitude of the drug mass considered in the parameters used to 
assess the efficiency of aerosol delivery and examples of techniques to quantify them. 
 
Figure 2: Figure 2: (A) The MicroSprayer™ and (B) Dry Powder Insufflator™ 
(Reproduced with permission of Penn-Century, Inc., Philadelphia, PA)  
 
Figure 3: Examples of (A) The Modified Whole Body exposure chamber (modified from 
[109]) and (B) The noseonly exposure chamber (ADG Developments, Ltd, Herts, UK) 
 
Figure 4: SPECT scan 3 h after inhalation. A: series of transversal (apex-to-base) and 
coronal (dorsal-to-ventral) slices of 99mTc-PSL retention in lungs of dog 4 around level of 
carina. Slices were calculated at a distance of 2 mm apart. Retention of 99mTc-PSL is 
overlaid in color scale over a ventilation scan in gray scale performed earlier. B: series of 
sagital (right-to-left lateral) slices of 99mTc-PSL retention in lungs of dog 4 and planar 
image from dorsal view of 99mTc-PSL deposit in lungs and PSL accumulation in trachea 
at site of ciliar obstruction because of inflation of cuff of endotracheal tube. Planar image 
was taken at beginning of SPECT scan 2.5 h after end of inhalation (from [151]). 
(PSL=polystyrene particles). 
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